Literature DB >> 9684575

Role of cytology in the intraoperative diagnosis of central demyelinating disease.

J Raisanen1, H S Goodman, D F Ghougassian, C G Harper.   

Abstract

OBJECTIVE: To determine the usefulness of cytology in the intraoperative diagnosis of central demyelinating disorders. STUDY
DESIGN: Smears of three multiple sclerosis (MS) plaques and two progressive multifocal leukoencephalopathy (PML) lesions prepared intraoperatively were examined and compared. The cytologic features were contrasted with those of infiltrating astrocytomas.
RESULTS: The preparations of demyelinating lesions revealed normal or reactive astrocytes and large numbers of foamy macrophages, the key diagnostic finding. The preparations of the lesions of PML contained virally infected oligodendrocytes. The specific cell types were identified easily because cytoplasmic margins could be distinguished.
CONCLUSION: Cytologic preparations of lesions of PML and MS permitted rapid identification of the diagnostic features and distinguished them from infiltrating astrocytomas, the most important lesion in the differential diagnosis. The findings demonstrated the utility of cytology in the diagnosis of central demyelinating diseases.

Entities:  

Mesh:

Year:  1998        PMID: 9684575     DOI: 10.1159/000331966

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  2 in total

1.  Intraoperative diagnosis of central nervous system lesions: Comparison of squash smear, touch imprint, and frozen section.

Authors:  Vikram Nanarng; Sunitha Jacob; Debahuti Mahapatra; Jacob E Mathew
Journal:  J Cytol       Date:  2015 Jul-Sep       Impact factor: 1.000

2.  Cytology of progressive multifocal leukoencephalopathy revisited: A case report with special reference to JC polyomavirus-infected oligodendrocytes and astrocytes.

Authors:  Mieko Doi; Keisuke Ishizawa; Kei Ikeda; Kazuo Nakamichi; Yoshihiko Nakazato; Toshimasa Yamamoto; Atsushi Sasaki
Journal:  Cytopathology       Date:  2021-08-14       Impact factor: 1.286

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.